Xtrana Wins US Patent for DNA Extraction Matrices | GenomeWeb

NEW YORK, Oct. 11 – Xtrana has been issued a US patent for a family of its nucleic acid extraction matrices, the company said on Wednesday.

The patent, numbered 6,291,166 and entitled "Nucleic Acid Archiving,” represents “the foundation technologies” for Xtrana products, according to a company statement.

The matrices, called Xtra Bind, capture and stabilize DNA and RNA and facilitate enzymatic manipulation of the nucleic acid, which Xtrana says results in “an extremely rapid and efficient extraction protocol.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.